Insider buying last 90 days
No open-market insider purchases were filed for LQDA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Liquidia's stock moved this week on a patent settlement with United Therapeutics, which permits continued sales of YUTREPIA for pulmonary arterial hypertension in exchange for defined net payments through April 2027. Separate coverage framed Liquidia as an "affordable growth" story, citing strong revenue and earnings growth alongside a high trailing P/E but more reasonable forward valuation metrics. The company also confirmed it will report third-quarter 2026 results on 10 November, with a live webcast at 8:30 a.m. Eastern.
Shares closed at $47.87, up 7.8% on the day, but remain below both the 50-day average of $49.99 and the 200-day average of $54.45, with the 50-day below the 200-day. The GekkoIndex reads 55.1, placing it in the Neutral zone, down 2.5 points over five sessions. Gekko Fair Value stands at $51.98, putting the current price 7.9% below that level.
Liquidia reports quarterly results on 10 November, zero days away, placing earnings risk inside the typical 20-trading-day holding window; the prior release saw an 18.1% reaction on an EPS miss of $0.74 versus $0.76 expected, with 3 beats in the last 8 quarters and an average absolute reaction of 12.8%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged a 11.6% gain over 5 years, rising in 5 of them. Analyst consensus across 8 firms, with 6 buy and 2 hold ratings, carries a target of $54.38.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Liquidia scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Averages disagree
Close $57.41 sits between the 50-day ($48.96) and 200-day ($54.71) averages, or the averages disagree.
See the chart48.5, Neutral
Reading 48.5 is in the Neutral zone.
See the GekkoIndex6.9% above
Price is 6.9% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 109 days
Next report Mar 4, 2027, 109 days away — outside a typical 20-trading-day hold.
See earnings+12.3% on average
From this point in the calendar, the next 20 trading days averaged +12.3% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Liquidia closed at $57.41 on Nov 13, 2026, +102.8% over the past year, inside a 52-week range of $22.31 to $93.61.
Use the left and right arrow keys to read daily values.
Put LQDA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Liquidia works in biopharmaceuticals, creating, manufacturing, and bringing to market treatments meant to address important unmet needs among patients across the United States. Among its development efforts, the company is working on YUTREPIA, an inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension. This program represents a central piece of its pipeline.
Alongside its work on new treatments, Liquidia also sells a generic injectable version of treprostinil to patients in the U.S. market, giving the company both a commercial product and a pipeline asset aimed at the same underlying condition.
Liquidia was established in 2004 and keeps its headquarters in Morrisville, North Carolina. Its shares trade on the NASDAQ under the ticker LQDA.
Liquidia’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.5, in the Neutral zone, down 7.8 points over five sessions.
Down 7.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | +10.4% | +35.9% | ||
| Accumulation | 210 | +2.8% | +2.6% | ||
| Neutral (current zone) | 413 | +0.8% | +6.0% | ||
| Distribution | 50 | −1.3% | +5.2% | ||
| Selling | 6 | Too few readings yet | |||
Average LQDA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Liquidia trades 6.9% above Gekko Fair Value of $53.68, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Liquidia shares are worth, recalculated every trading day.
$53.68
Gekko Fair Value, Nov 14, 2026
6.9% Overvalued
At the end of Aug 2026 the price was 30.2% below the estimate.
No open-market insider purchases were filed for Liquidia, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for LQDA in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in LQDA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold LQDA.
Liquidia reports on Mar 4, 2027, before the open (109 days away), and beat the EPS estimate in 3 of its last 8 reports.
Mar 4, 2027
Expected before the open, 109 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | $0.74 est $0.76 | $171.7M est $168.5M | −18.1% |
| May 11, 2026 | $0.52 est $0.34 | $132.9M est $119.4M | +33.8% |
| Mar 5, 2026 | $0.15 est $0.08 | $92.02M est $88.59M | +4.8% |
| Nov 3, 2025 | −$0.04 est −$0.45 | $54.34M est $80.72M | +14.6% |
| Aug 12, 2025 | −$0.49 est −$0.43 | $8.84M est $14.30M | +18.9% |
| May 8, 2025 | −$0.45 est −$0.42 | $3.12M est $4.16M | −1.7% |
| Mar 19, 2025 | −$0.46 est −$0.38 | $2.92M est $3.31M | +4.7% |
| Nov 13, 2024 | −$0.39 est −$0.37 | $4.45M est $4.63M | −5.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Liquidia is $60.75, +5.8% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | H.C. Wainwright | $76 | +32.4% |
| Nov 11 | Wells Fargo | $40 | −30.3% |
| Nov 11 | Raymond James | $77 | +34.1% |
| Nov 11 | Bank of America Securities | $54 | −5.9% |
| Nov 10 | Jefferies | $62 | +8.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Liquidia averaged +12.3% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.7% | 2 of 5 |
| Next 10 trading days | +4.6% | 3 of 5 |
| Next 15 trading days | +9.7% | 4 of 5 |
| Next 20 trading days | +12.3% | 4 of 5 |
| Next 30 trading days | +29.7% | 4 of 5 |
For scale, LQDA’s typical 20-trading-day move in either direction is about 11.5%.
Liquidia’s market cap is $5.17B and revenue of $621.9M over the last twelve months.
Coverage of Liquidia this week reads positive: 6 positive, 3 neutral and 2 negative headlines.
Liquidia’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Liquidia’s market cap is $5.17B at the Nov 13, 2026 close of $57.41, with 90.11M shares outstanding.
The consensus analyst 12-month price target for Liquidia is $60.75, +5.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Liquidia is overvalued: the Nov 13, 2026 close of $57.41 is 6.9% above Gekko Fair Value of $53.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Liquidia is expected to report on Mar 4, 2027, before the market opens (109 days away). Analysts expect earnings of $0.39 per share on revenue of $224.7M. Liquidia beat the earnings estimate in 3 of its last 8 reports, moving 12.8% on average across the report.
Liquidia’s 52-week high is $93.61 and its 52-week low is $22.31; it closed at $57.41 on Nov 13, 2026, +102.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.